Breast Cancer Invasion and Metastasis by mPRα Through the PI3K/Akt Signaling Pathway

Invasive breast cancer is the most common type of malignancy in women worldwide. However, the mechanism responsible for breast cancer metastasis is still unclear and needs further illustration. It has been proven that matrix metallopeptidase 9 (MMP-9) promotes metastasis of the cancer cells. However, the interaction between mPRα and MMP-9 has not been studied. Therefore, in the present research, the effect of MMP-9 on the malignant progression of invasive breast cancer promoted by membrane progesterone receptorα (mPRα) was investigated. The results showed that the protein expression of mPRα, p-Akt and MMP-9 increased in the cancerous tissues compared to that of the noncancerous breast tissue. Furthermore, a positive correlation was found between mPRα and C-erbB-2, as well as the number of involved local lymph nodes. On the other hand, a negative correlation was observed between mPRα and estrogen receptors (ER) along with progesterone receptors (PR). Similarly, a positive association was found between MMP-9 and the number of involved local lymph nodes. Besides, the high expression of MMP-9 also had a positive correlation with the tumor size. However, the high level of MMP-9 had a negative correlation with ER and PR. In addition, there was a positive correlation between mPRα and p-Akt together with MMP-9. The results confirm that mPRα was a major marker of harmful prognosis and it promoted the expression of MMP-9 during invasion to the local lymph nodes through the pathway of PI3K/Akt. The present study provided a novel therapeutic strategy to inhibit breast cancer growth by preventing mPRα signaling pathway.

[1]  M. L'hermite.  HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT , 2013, Climacteric : the journal of the International Menopause Society.

[2]  Ash A. Alizadeh,et al.  Towards a novel classification of human malignancies based on gene expression patterns , 2001, The Journal of pathology.

[3]  B. Nielsen,et al.  MMP-9 Is Differentially Expressed in Primary Human Colorectal Adenocarcinomas and Their Metastases , 2006, Molecular Cancer Research.

[4]  P. Thomas,et al.  Membrane Progesterone Receptors (mPRs) Mediate Progestin Induced Antimorbidity in Breast Cancer Cells and Are Expressed in Human Breast Tumors , 2012, Hormones and Cancer.

[5]  Nancy Y. Villa,et al.  Metalloregulation of yeast membrane steroid receptor homologs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Buchholz,et al.  Prognostic significance of occult axillary lymph node metastases after chemotherapy‐induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer , 2009, Cancer.

[7]  William R Sellers,et al.  PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. , 2003, Cancer treatment and research.

[8]  William R. Sellers,et al.  PI3K/PTEN/Akt Pathway , 2004 .

[9]  G. Nagaraj,et al.  Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer , 2015, Breast Cancer Research and Treatment.

[10]  H. Kuhl,et al.  Progesterone – promoter or inhibitor of breast cancer , 2013, Climacteric : the journal of the International Menopause Society.

[11]  B. Rowan,et al.  Genes related to estrogen action in reproduction and breast cancer. , 2005, Frontiers in bioscience : a journal and virtual library.

[12]  J. Dong,et al.  Steroid and G protein binding characteristics of the seatrout and human progestin membrane receptor alpha subtypes and their evolutionary origins. , 2007, Endocrinology.

[13]  H. Randeva,et al.  Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. , 2006, Molecular endocrinology.

[14]  N. Youssef,et al.  Association of Fascin and matrix metalloproteinase-9 expression with poor prognostic parameters in breast carcinoma of Egyptian women , 2014, Diagnostic Pathology.

[15]  Ya-xin Lou,et al.  YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways , 2015, Journal of Cancer.

[16]  P. Thomas,et al.  Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Naumov,et al.  Critical steps in hematogenous metastasis: an overview. , 2001, Surgical oncology clinics of North America.

[18]  P. Thomas,et al.  Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Griffioen,et al.  Tumor endothelium is characterized by a matrix remodeling signature. , 2009, Frontiers in bioscience.

[20]  A. Gompel.  Micronized progesterone and its impact on the endometrium and breast vs. progestogens , 2012, Climacteric : the journal of the International Menopause Society.

[21]  D. Edwards,et al.  Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. , 2007, Molecular endocrinology.

[22]  J. Li,et al.  Antisense and Dominant-Negative AKT2 cDNA Inhibits Glioma Cell Invasion , 2004, Tumor Biology.